Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.06 USD
Change Today -0.01 / -0.08%
Volume 1.4M
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 5:20 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Snapshot

Open
$12.11
Previous Close
$12.07
Day High
$12.14
Day Low
$11.97
52 Week High
01/27/15 - $17.11
52 Week Low
06/29/15 - $11.57
Market Cap
1.7B
Average Volume 10 Days
1.5M
EPS TTM
$-1.25
Shares Outstanding
125.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (IRWD)

ironwood pharmaceuticals inc (IRWD) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (IRWD) Details

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has collaboration agreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, as well as in China, Hong Kong, and Macau. The company also has license agreements with Almirall, S.A. and Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, as well as Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

464 Employees
Last Reported Date: 02/18/15
Founded in 1998

ironwood pharmaceuticals inc (IRWD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.3K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $388.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $377.6K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $371.0K
Compensation as of Fiscal Year 2014.

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals Seeks Acquisitions

Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD) announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022. Ironwood intends to use the net proceeds of the offering to strengthen its balance sheet, improve its capital structure and the acquisition of, or investment in, businesses or other strategic assets, and to pay the cost of the convertible note hedge transactions.

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 01:20 PM

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 01:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Peter M. Hecht, Co-Founder, Chief Executive Officer and Director.

Ironwood Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM

Ironwood Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Thomas Graney, Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $12.06 USD -0.01

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $7.13 USD -0.049
Nektar Therapeutics $11.89 USD -0.23
Progenics Pharmaceuticals Inc $6.97 USD -0.12
Sucampo Pharmaceuticals Inc $16.34 USD -0.74
Theravance Inc $16.87 USD -0.55
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.8x
Price/Book 25.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.